Ewing's Sarcoma/Peripheral Neuroectodermal Tumor

Key Points:


Ewing’s Sarcoma (ES) and Peripheral Neuroectodermal Tumor (PNET) are part of a spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors. These diseases are associated with malignant small-cell tumors that can be found both in the bone and soft tissues of the extremities, but can also present in the axial skeleton. This family of tumors has the same chromosomal translocation t(11;22). Male patients outnumber female patients, and the femur is the most common site of origin. ES and PNET have similar presentations and treatment. There is usually a soft tissue mass associated with the bone lesion. There are no specific abnormal laboratory values that are diagnostic of these tumors. Elevated LDH level indicates a poor prognosis.


The Ewing’s sarcoma family of tumors represent the second most common primary bone malignancy affecting children and adolescents, after osteosarcoma. The peak incidence for these tumors is between 10 to 15 years of age. There is a slight male predominance. These tumors affect mainly Caucasians and are extremely uncommon among blacks and Asians. 

Imaging Studies:

The plain radiographs of a patient with Ewing’s Sarcoma will usually demonstrate diffuse destruction of the bone that extends through the cortex, and would reveal a soft-tissue component. These lesions are classically associated with an onion-skin periosteal reaction.  The extraosseous soft tissue mass and the medullary canal involvement are best seen on MRI. Technetium bone scan is most useful in finding occult bone metastasis. Approximately 20% of these patients present with metastatic disease (lung is the most common site). The utility of PET or integrated PET-CT for initial staging is unclear and remains investigational.


The treatment for ES/PNET is a combination of chemotherapy and local control, either by surgery, radiation therapy, or a combination of both. The drugs commonly used include vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide. A multi-agent chemotherapy protocol using these agents is applied for 2-4 cycles before the management of the primary tumor. Surgical resection is recommended if the consequences of the resection do not have a significant impact on function. If the primary tumor cannot be resected without undue morbidity, or is unresectable, radiation alone can be used with good local control. Postoperative radiation can be used in the setting of close or positive margins. After the management of the primary tumor, a post-operative course of the same agents is usually continued.

For lesions involving either the upper or lower extremity, a limb salvage surgical resection can improve functional outcome without sacrificing local disease control as long as complete tumor resection is anatomically possible.  However, in some instances amputation or rotationplasty will result in the most functional outcome. Allografts and metal endoprostheses are common means of reconstructing bone defects that result from sarcoma resections. Expandable prostheses have been developed for reconstruction in skeletally immature children and allow lengthening of the limb, thus making limb salvage surgery an option in the younger skeletally immature patient.


Related Videos:

POSNAcademy logo

Peer Reviewed Video Learning

View Related Videos


  1. Arkader A, Gebhardt MC, Dormans JP. Bone and Soft-Tissue Tumors. Lovell and Winter's Pediatric Orthopaedics. Philadelphia, PA: Lippincott Williams & Wilkins; 7th ed. 2014.
  2. Askin FB, Rosai J, Sibley RK, et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 1979; 43:2438.
  3. Bacci G, et al. Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006;45(4):469-475.
  4. Bacci G, et al. Role of surgery in local treatment of Ewing’s Sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep 2004;11(1):111-120. 
  5. Campanacci M. Bone and Soft Tissue Tumors, 2nd, Springer Verlag, New York 1999. p.653.
  6. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66:887.
  7. Dunst J, Jurgens H, Sauer R. Radiation therapy in Ewing’s sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;32:919.
  8. Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479.
  9. Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25:874.
  10. Györke T, Zajic T, Lange A, et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 2006; 27:17.
  11. Hawkins DS, Rajendran JG, Conrad EU 3rd, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002; 94:3277.
  12. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22.
  13. Mankin HJ. Ewing sarcoma. Curr Opinion Ortho 2000; 11:479.
  14. McCarville MB, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005; 184:1293.
  15. Mendenhall CM, Marcus RB Jr, Enneking WF, et al. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer 1983; 51:913.
  16. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163.
  17. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004; 22:2873.
  18. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 1997; 202:237.
  19. Parasuraman S, Langston J, Rao BN, et al. Brain metastases in pediatric Ewing sarcoma and rhabdomyosarcoma: the St. Jude Children's Research Hospital experience. J Pediatr Hematol Oncol 1999; 21:370.
  20. Paulino AC. Late effects of radiotherapy for pediatric extremity sarcomas. Int J Radiat Oncol Biol Phys 2004;60(1):265-274.
  21. Paulino AC, Nguyen TX, Mai WY. An analysis of primary site control and late effects according to local control modality in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 2007;48(4):423-429.
  22. Pritchard D, Dahlin D, Dauphine R. Ewing’s sarcoma: a clinicopathological and statistical analysis of patients surviving five years or longer. J Bone Joint Surg Am 1975;57:10.
  23. Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435.
  24. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000; 82:667.

Top Contributors:

Henock T. Wolde-Semait MD
Scott Rosenfeld MD